CANADA – 2025/10/12: In this photo illustration, the Abbott Laboratories logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)
SOPA Images/LightRocket via Getty Images
Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, aligning with expectations, while the total annual adjusted EPS reached $5.15, indicating a 10% growth. Can the stock gain momentum from this point onward despite the revenue shortfall? It won’t be an easy task.
However, before we delve into the reasons, if you are looking for a less volatile investment compared to holding an individual stock like ABT, consider the High Quality Portfolio. It has consistently outperformed its benchmark—a mix of the S&P 500, Russell, and S&P MidCap indexes—and has achieved returns surpassing 105% since its launch. Why is this the case? As a collective, the HQ Portfolio stocks generated improved returns with reduced risk compared to the benchmark index; it offered a steadier experience, as reflected in HQ Portfolio performance metrics. Additionally, refer to – The Binary Bet: QuantumScape’s Path To Doubling.
How Did Core Operations Stack Up?
Organic sales growth decreased to 3% during the quarter, influenced by reduced demand in some areas. The adjusted gross margin increased by 20 basis points to 57.1%, and the operating margin expanded by 150 basis points to 25.8%, demonstrating effective cost management. Full-year results displayed double-digit EPS growth, supported by a productive pipeline of new products. Check Abbott’s financials for additional information.
Segment Breakdown
- Medical Devices: This segment continues to shine with strong demand in structural heart and neuromodulation. Freestyle Libre maintained impressive growth, although overall device sales encountered some challenges from year-over-year comparisons. The unit contributed significantly to organic growth despite broader economic pressures.
- Diagnostics: Diagnostics revenue showed ongoing normalization following COVID, with molecular diagnostics stabilizing. The Exact Sciences acquisition—valued at up to $23 billion and scheduled to close in Q2 2026—aims to enhance this sector with cancer screening tools like Cologuard, targeting over $12 billion in annual sales post-acquisition. However, integration risks and potential dilution through 2027 temper short-term excitement.
- Nutrition: Nutrition sales declined, affected by dynamics in the infant formula market and softer regional demand. Organic growth fell short of broader company trends, raising concerns regarding this segment’s future path. Management underscored the significance of innovation pipelines, but clarity remains limited.
- Established Pharmaceuticals: Established Pharma provided stable performance, with generic erosion counterbalanced by volume in emerging markets. This segment made consistent contributions, though growth has slowed.
What Signals Does 2026 Guidance Send?
Guidance projects a 6.5%-7.5% organic sales growth and an adjusted EPS around $5.68 at the midpoint, aligning with consensus expectations. This indicates a moderate acceleration, but lingering questions remain: Will Nutrition recover? Can Exact Sciences perform without impacting earnings negatively?
What’s Behind The Valuation Dynamics?
Currently priced at around $109 per share, Abbott trades at 21 times its trailing adjusted EPS of $5.15. This represents a decrease from the three-year average P/E of 24 times, which seems justified given the slowing sales growth in Nutrition and the ongoing uncertainties regarding the Exact Sciences acquisition. While our current price estimate for ABT stock is $144, a downward revision seems imminent to account for the latest financial results.
Is the P/E compression fair? At a P/E of 21 times trailing earnings, Abbott appears less expensive compared to its recent history, but this multiple reflects genuine challenges. The forward P/E based on guidance (19 times) indicates potential stability, but slowdowns in Nutrition and uncertainties surrounding acquisitions limit optimism. Additionally, see how Abbott’s valuation is compared to its peers.
What catalysts could drive re-rating? Potential upside depends on Exact Sciences synergies realizing more quickly than anticipated, stabilization in Nutrition, and seamless execution in high-growth devices like Libre. Consistently exceeding guidance could help justify higher multiples.
What caps the potential? Downside risks include persistent weakness in Nutrition, regulatory challenges with the Exact Sciences acquisition, and overall caution in medtech spending. Revenue misses like those seen in Q4 exacerbate valuation pressures, possibly leading to additional compression.
Moreover, investing in a single stock without thorough analysis carries risks. Consider the Trefis Reinforced Value (RV) Portfolio, which has surpassed its all-cap stocks benchmark (a combination of the S&P 500, S&P mid-cap, and Russell 2000 indices) to deliver solid returns for investors. What accounts for this success? The quarterly rebalanced mix of large-, mid-, and small-cap RV Portfolio stocks has offered a nimble approach to seize favorable market conditions while mitigating losses when markets decline, as detailed in RV Portfolio performance metrics.
The Bottom Line
Abbott’s Q4 highlights robust EPS amid revenue challenges, though its valuation at 21 times trailing earnings appears reasonable given Nutrition struggles and uncertainties surrounding Exact Sciences. A price estimate lower than $144 seems sensible, positioning the stock for modest upside at best from current levels rather than significant rallies.